Abstract
To determine the incidence of malignancy and site-specific malignancies in Japanese patients with rheumatoid arthritis (RA). In a prospective large observational cohort study named IORRA, 7,566 patients with RA were enrolled from April 2001 to April 2005 and were followed up to October 2005. Occurrence of malignancy was originally collected by patient reports of IORRA survey biannually from April 2001 to October 2005, and was confirmed by medical records. Standardized incidence rate (SIR) of the observed-to-expected cancer incidence and 95% confidence intervals (95% CI) were then calculated. Factors obtained at first enrollment in IORRA were assessed for association with risk of malignancy using the Cox proportional hazards model. A total of 177 malignancies in 173 patients (58 in men, 115 in women) were identified during the observation period of 25,567 person-years. The age- and sex-standardized incidence rate of malignancy was 437.1 (men, 706.8; women, 366.1) per 100,000 person-years. The SIR of malignancy was slightly excess (SIR 1.18, [95% CI 1.02–1.37]) in all patients, but 1.29 (95% CI 0.99–1.67) in men, and 1.13 (95% CI 0.94–1.36) in women. A significant excess of lymphoma (SIR 6.07, [95% CI 3.71–9.37]) and lung cancer (SIR 2.29, [95% CI 1.57–3.21]), whereas decreased incidence of colorectal cancer (SIR 0.49, [95% CI 0.26–0.83]), were found. Male gender and older age were identified as risk factors for malignancy. A slight excess in the incidence of overall malignancy and highly excess of lymphoma in Japanese RA patients was demonstrated.
Similar content being viewed by others
References
Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67
Young A, Koduri G, Batley M et al (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350–357
Kuroda T, Tanabe N, Harada T et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 24:445–451
Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331
Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393
Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45
Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 37:388–397
Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37:31–38
Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007) Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56:790–798
Geborek P, Bladstrom A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703
Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R (1984) Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43:128–131
Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580–1586
Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158
Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–1420
Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764
Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757
Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502
Georgescu L, Quinn GC, Schwartzman S, Paget SA (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804
Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701
Kojima M, Itoh H, Hirabayashi K et al (2006) Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract 202:679–685
Shinomiya F, Mima N, Nanba K et al (2008) Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheumatol 18:165–169
Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, Shidara K, Hara M, Momohara S, Taniguchi A, Kamatani N, Yamanaka H (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol (in press)
Yamanaka H, Inoue E, Singh G et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289
Yamada T, Nakajima A, Inoue E et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663
Nakajima A, Kamitsuji S, Saito A et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157
Matsuda Y, Singh G, Yamanaka H et al (2003) Validation of a Japanese version of the Stanford health assessment questionnaire in 3, 763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788
Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2008) Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641–648
Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS (1992) Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19:1462–1465
Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996) Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 39:325–329
Hoshida Y, Tomita Y, Zhiming D et al (2004) Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443–449
Rizzi R, Curci P, Delia M et al (2009) Spontaneous remission of “Methotrexate-associated lymphoproliferative disorders” After discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26:1–9
Miyazaki T, Fujimaki K, Shirasugi Y et al (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106–1109
Bernatsky S, Clarke A, Suissa S (2008) Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 59:266–269
Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56:1433–1439
Acknowledgments
The IORRA study is supported by a research grant from 36 pharmaceutical companies: Abbott Japan Co., Ltd., Asahikasei Kuraray Medical Co., Ltd., Asahikasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Banyu Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Fine Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Japan Tobacco Inc., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Mitsubishi Chemical Medience Corporation, Mitsubishi Tanabe Pharma Corporation, Nippon Chemiphar Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc.. Sanofi-Aventis K.K, Santen Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sekisui Medical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Torii Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., UCB Japan Co., Ltd., Wyeth K.K., and Zeria Pharmaceutical Co., Ltd.
Conflict of interest statement
The authors have declared no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamada, T., Nakajima, A., Inoue, E. et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 31, 1487–1492 (2011). https://doi.org/10.1007/s00296-010-1524-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1524-0